Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Controlled study of oral pramiconazole in the treatment of pityriasis versicolor

A 28-day, randomized, multicenter, double-blind, placebo-controlled, dose-finding study evaluated the efficacy and tolerability of oral pramiconazole in 147 patients with pityriasis versicolor. The pramiconazole dosing groups all used a once-daily regimen and comprised 100 mg (x 1 day; group A); 200 mg (x 1 day; group B);  200 mg (x 2 days; group C); 400 mg (x 1 day; group D); 200 mg (x 3 days; group E); or placebo (x 3 days). Patients were evaluated at screening, days 0, 14 and 28. The primary endpoint was the proportion of patients with "effective treatment" at day 28. "Effective treatment" was defined as negative microscopy finding (mycological cure) and either erythema, desquamation ...